XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
shares in Thousands, $ in Thousands
Oct. 01, 2021
Jan. 01, 2021
Current assets:    
Cash and cash equivalents $ 567,325 $ 319,217
Short-term investments 835,406 887,319
Trade receivables, net 179,493 160,875
Inventory 28,240 20,973
Prepaid expenses and other current assets 51,564 57,011
Total current assets 1,662,028 1,445,395
Long-term investments 362,218 330,751
Property and equipment, net 99,838 67,384
Deferred tax assets, net 125,295 156,711
Goodwill 63,684 63,684
Other long-term assets 134,678 73,408
Total assets 2,447,741 2,137,333
Current liabilities:    
Accounts payable 24,314 23,632
Accrued compensation and benefits 53,306 51,189
Accrued clinical trial liabilities 70,618 52,251
Rebates and fees due to customers 31,120 20,683
Accrued collaboration liabilities 35,403 12,456
Other current liabilities 54,747 44,447
Total current liabilities 269,508 204,658
Long-term portion of deferred revenues 9,444 3,755
Long-term portion of operating lease liabilities 52,252 49,086
Other long-term liabilities 4,090 721
Total liabilities 335,294 258,220
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 316,305 and 311,627 at September 30, 2021 and December 31, 2020, respectively 316 312
Additional paid-in capital 2,422,323 2,321,895
Accumulated other comprehensive income 1,481 4,476
Accumulated deficit (311,673) (447,570)
Total stockholders’ equity 2,112,447 1,879,113
Total liabilities and stockholders’ equity $ 2,447,741 $ 2,137,333
Common Stock, Shares, Issued 316,305 311,627